Dynavax

$4.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.19%) Today
+$0.04 (+0.96%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Dynavax and other stocks, options, and ETFs commission-free!

About DVAX

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA. The listed name for DVAX is Dynavax Technologies Corporation Common Stock.

CEO
Ryan Spencer
Employees
231
Headquarters
Emeryville, California
Founded
1996
Market Cap
457.22M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.23M
High Today
$4.28
Low Today
$4.06
Open Price
$4.20
Volume
2.00M
52 Week High
$12.44
52 Week Low
$1.80

Collections

DVAX Earnings

-$0.65
-$0.43
-$0.22
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 10, After Hours

You May Also Like